Women pregnant between 11-14 weeks gestation will be enrolled with blood samples collected to evaluate for preeclampsia.
To collect relevant pregnancy outcome data, medical history, and blood samples from pregnant women carrying a singleton fetus undergoing non-invasive screening for early, preterm and term pre-eclampsia (PE) starting at 11 weeks 0 days to 14 weeks 0 days (≥11 - ≤14) gestation in support of validating the Labcorp Preeclampsia ScreenTM assay. Data will be used to examine assay performance and develop new testing methods.
Study Type
OBSERVATIONAL
Enrollment
6,550
Valley Perinatal
Glendale, Arizona, United States
Baseline serum samples will be used to evaluate the performance of the Labcorp Preeclampsia Screen assay
The results of the Preeclampsia Screen assay will be compared to pregnancy outcome data to evaluate how well the assay predicted early onset PE (\<34 weeks gestational age) and preterm PE (\<37 weeks gestational age).
Time frame: From enrollment at 10-14 weeks gestation until pregnancy outcome is available, up to 36 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Delaware Center for Maternal and Fetal Medicine
Newark, Delaware, United States
NOT_YET_RECRUITINGD&H National Research Centers
Miami, Florida, United States
TERMINATEDSouthern Clinical Research Associates
Metairie, Louisiana, United States
NOT_YET_RECRUITINGBeth Israel Deaconess Medical Center
Boston, Massachusetts, United States
NOT_YET_RECRUITINGCooper University Health Care
Camden, New Jersey, United States
NOT_YET_RECRUITINGNew Jersey Perinatal Associates
Livingston, New Jersey, United States
RECRUITINGRutgers Robert Wood Johnson Medical School
New Brunswick, New Jersey, United States
RECRUITINGCapital Health
Pennington, New Jersey, United States
RECRUITINGColumbia University Medical Center
New York, New York, United States
NOT_YET_RECRUITING...and 11 more locations